Connect Biopharma is trading 6.35% down at $1.03 in pre-market, with no confirmed overnight announcement explaining the decline.
- On September 30, the company reported positive preliminary Phase 2 COPD results: rademikibart reduced treatment failure by 81% through Week 4 versus placebo.
- That prior-day news does not clearly explain the opposite-direction pre-market move, so its cause remains unconfirmed.